Genome-wide association studies (GWAS) have discovered germline genetic variation associated with type 2 diabetes risk (1-4). One of the largest GWAS, involving DNA taken from individuals of European descent, and conducted by the DIAGRAM (DIAbetes Genetics Replication and Meta-analysis) consortium identified 65 loci associated with type 2 diabetes risk (1). However for most of these loci, the precise identity of the affected gene and the molecular mechanisms underpinning the altered risk are not known.
Similar to other complex polygenic diseases, the lack of protein-coding variation at the majority of these loci has led many to believe that the disease-associated variation must result in changes in the level of gene expression. This is predicted to affect the amount or nature of protein produced resulting in compromised cellular function and ultimately altered disease risk. It is this hypothesis that has led many to conduct expression quantitative trait loci (eQTL) studies, where the disease-associated genotype is correlated with expression of cislinked transcripts. Whilst there have been some successes when using such an approach (5; 6), the presence of multiple known and unknown confounding factors that can affect gene expression means few disease-associated loci are robustly associated. Allelic expression profiling provides an alternative and direct way to measure the effect of cis-regulatory variation on gene expression. By measuring transcripts from each allele of a gene (using a SNP as a marker to differentiate between the two mRNA copies) the effect of trans-acting factors on gene expression is essentially removed as the output from one allele serves as a within-sample control for the other.
The known tissue-specificity of gene expression regulation means that the most informative studies will measure transcript levels in the specific tissue(s) relevant to the disease. In the case of type 2 diabetes, characterisation of physiological responses (e.g. stimulus-induced insulin secretion, insulin sensitivity) suggests most loci are associated with defects in pancreatic beta cell function (2; 3; 7). Therefore there is a real need to measure gene expression in human beta cells (or whole islets as these have been shown to be a suitable proxy (8) ). There have however been very few reports linking type 2 diabetes-associated variation with islet gene expression using the classical eQTL approach (9; 10).
In this report we provide one of the first pieces of evidence to support the theory that for a large proportion of loci associated with predisposition to type 2 diabetes the variants affect the expression of known protein-coding genes. Furthermore by pinpointing genes with allelic expression imbalances we highlight the genes likely to be involved in disease pathogenesis.
RESEARCH DESIGN AND METHODS

Tissue and nucleic acid extraction
Snap-frozen islets were purchased from ProCell Biotech (Newport Beach, CA, USA) where islets had been collected with ethical permission at source. Donor characteristics are presented in Supplementary Table 1 . Islet purity and viability was determined by dithizone and fluorescein diacetate/propidium iodide staining, respectively. RNAlater-ICE (Life Technologies, Carlsbad, CA, USA) was used to transition the tissue to a state where RNA could be extracted using the miRVana miRNA isolation kit, as per the manufacturers' instructions and using the total RNA extraction protocol. Small amounts of genomic DNA were co-eluted upon RNA extraction. Whole-genome amplification was subsequently carried out using the REPLI-g Mini kit (Qiagen, Venlo, Netherlands).
Genotyping and quantitative reverse transcriptase-PCR (qRT-PCR)
To find heterozygous samples suitable for allelic expression measurements whole genome amplified genomic DNAs were first genotyped. Sanger sequencing or TaqMan SNP genotyping assays were used to confirm that in all cases where allelic expression was determined the respective lead type 2 diabetes-associated SNP was also heterozygous. For allelic expression analyses total RNA was DNase-treated using the Turbo DNA-free kit (Life Technologies). DNase-treated RNA was subsequently reverse transcribed using the SuperScript VILO cDNA synthesis system (Life Technologies). For each SNP duplicate wells were used to amplify cDNA and ~5ng genomic DNA in all heterozygous samples. 
Validation of TaqMan SNP genotyping assays as a robust method for determining allelic expression
The reproducibility of the allelic expression measurement was determined by comparing values generated from independent cDNAs that were reverse transcribed and amplified by real-time PCR on different days and PCR plates (r2=0.72, p=1.8 x 10 -62 ; Fig. 2A ). To further demonstrate the robustness of this technique allelic expression values for 5 genes were compared between 2 linked SNPs residing in the same gene (r2=0.67, p=5.7 x 10 -16 ; Fig. 2B ).
Identification of allelic expression imbalance at GWAS loci
Significant (unadjusted p<0.05) allelic expression imbalance (AEI) was observed for 7/14 genes tested (Table 1 for CAMK2B and HMG20A due to the position of the only other proxy exonic SNP on the transcript (SNP either too close to a splice site to allow for assay to be designed to measure mature mRNA, or near a sequence of low complexity precluding assay design).
Islet eQTL analysis provides further evidence to support ANPEP as being the causal gene at this locus
One limitation of our approach is its reliance on the presence of exonic proxy SNPs, thus preventing testing of all candidate genes at a locus. Of the 7 genes where we identified significant AEI ANPEP exhibited by far the largest imbalance, with both SNPs tested showing ~50% difference between mRNA alleles. Therefore we predicted that we had most 
DISCUSSION
In this study we report that half of the type 2 diabetes SNPs examined had effects on allelic expression of nearby genes, consistent with a role for such variation in cis-regulation of islet gene expression. This figure is greater than genome-wide analyses of AEI which have generally reported 4-8% of common SNPs associated with the expression of at least one transcript (11; 12) . An enrichment of significant genotype effects on cis-linked gene expression has been reported for complex disease traits (13; 14) and our results suggest that effects on gene expression may play a significant role in mediating the genotype associations with type 2 diabetes.
We are aware of only one other published study reporting associations between gene expression levels and multiple type 2 diabetes-associated lead SNPs. Using global microarray data measuring gene expression in islets from 63 donors Taneera et al. reported a significant (p<0.001) cis-eQTL for 5/47 (11%) type 2 diabetes-associated SNPs (10) . Unfortunately none of the cis-eQTLs identified in their study could be tested in our study due to a lack of SNPs meeting our inclusion criteria (exonic and assay mapping purely to exonic sequence).
A comparison of the results from their study and ours illustrates some of the advantages and disadvantages of the respective techniques. Whilst our targeted allelic expression approach identifies a higher percentage (50% versus 11%) of genes regulated by cis-acting variation our approach is limited to genes with exonic SNPs in high linkage disequilibrium (r2>0.8)
with the lead type 2 diabetes-associated SNP. Indeed this dependence will also often preclude examining isoform-specific effects which may be substantial (15) Whilst this is, to our knowledge, the first report of a systematic use of allelic expression measurements in human islets to identify likely causal genes at type 2 diabetes GWAS loci, there are other published studies that have reported allelic imbalance in human islets at single loci. Kulzer et al. report allelic expression imbalance for two SNPs in ARAP1 (17), one of which (rs11603334) was also tested in our study. They report significant AEI for rs11603334 in 6 individuals with a mean AEI = 12.6% whereas our study fails to identify significant AEI (p=0.54) in the 7 heterozygous individuals tested. It is difficult to understand the reasons for such disparate findings, given that allelic expression should remove much of the confounding effects of trans-acting factors, but it may be that differences in methodology (TaqMan versus MALDI-TOF) and the small sample sizes (n=6-7) explain the lack of replication. Another study by Nica et al. analysed allelic expression for type 2 diabetes GWAS implicated genes using RNA-Seq in pancreatic beta cells from 11 donors. In support of our findings they also report AEI for rs5215 (KCNJ11) and rs11558471 (SLC30A8), albeit only in four samples and one sample, respectively (8).
The lack of reports detailing allelic expression imbalances for type 2 diabetes GWAS genes may be explained by the widespread use of non-targeted RNA-Seq methodologies. Whilst whole transcriptome RNA-Seq approaches provide researchers with an unparalleled resource to investigate all transcripts, its lack of targeting of specific transcripts means the sequencing depth at loci of interest is not as high as could be achieved using targeted approaches. An examination of two recent studies using RNA-Seq methods to quantify the islet transcriptome (18; 19) shows that the median RPKM (reads per kilobase per million mapped reads) for the genes at the 65 type 2 diabetes-associated GWAS loci is 8-9 RPKM. If one considers that current read lengths are ~50bp and typical human islet sequencing depths vary, but are perhaps currently ~50 million mapped reads per sample, then an average 25 reads will map to one exonic SNP. Fontanillas et al. calculate that 200 reads (equivalent to 8 samples) would
give 80% power to detect AEI of 1.5, whilst to detect an AEI =1.25 >500 mapped reads (>20 samples) would be needed (assuming a liberal type 1 error rate α = 5%) (20) . In our study we found an AEI ≤1.25 for 5/7 loci where AEI was significant. Therefore to replicate our findings using current non-targeted RNA-Seq technologies would likely require a number of heterozygous individuals which, given the difficulty in collecting large cohorts of human islets, is not likely to occur in the near future.
The significance of small AEIs (≤1.25) at 5 of the loci deserves discussion. Are such seemingly small imbalances of significant consequence to islet function? At one of these loci (SLC30A8) a missense SNP (rs13266634; W325R) is in complete LD (r2=1, D'=1) with the lead SNP (rs3802177) also examined for AEI. There is some evidence that functional nonsynonymous variants have co-evolved with regulatory variants so as to strengthen or diminish their functional impact (21) . This would suggest that the increase in expression of the risk versus non-risk allele is not directly altering disease risk in such cases, but rather moderating the effect of the non-synonymous variant, which is primarily responsible for the molecular deficit increasing disease risk. However, with respect to SLC30A8 it has recently been reported that heterozygous loss-of-function mutations, which are likely null alleles, protect against type 2 diabetes (22). This is strong evidence that the precise levels of SLC30A8 are important for beta cell function. Given that we measured increased levels of SLC30A8 transcripts originating from the risk, versus non-risk allele, one could speculate that it is the increase in SLC30A8 levels, rather than the presence of the missense variant, which increases type 2 diabetes risk. Indeed the sole study, to date, that examined the functional effects of the missense variant on zinc transporter activity, reported only a mild attenuation in zinc ion transporter activity in cells overexpressing the risk (R) allele of W325R, compared to cells expressing the non-risk (W) allele (23).
If we consider the other 6 loci where we observe significant AEI, two (ANPEP, KCNJ11)
have at least one missense variant within that gene and in high LD (r2>0.8) with the lead SNP, whilst at the NOTCH2 locus there is a missense SNP in a nearby gene (ADAM30).
Whether the SNP in ADAM30 is of consequence to the type 2 diabetes association is very questionable given its reported testis-specific expression (24) , and the very low expression we and others (8; 19) , have observed in human islets. Furthermore, small changes in expression of NOTCH2, as identified in this study, may be of significant consequence to the beta cell with experiments in mice showing that when only one copy of NOTCH2 is conditionally removed from Ngn3-positive cells (i.e. endocrine progenitors), the cells are diverted to an acinar fate (25) . Therefore it may be hypothesised that carriers of NOTCH2 
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For three genes (CAMK2B, HMG20A and WFS1) there are no non-synonymous variants in high LD (r2>0.8), strongly suggesting that at these loci, at least, alterations in gene expression are primarily involved in affecting type 2 diabetes risk. Our finding of a small AEI for WFS1 may be of significant consequence to the beta cell given that homozygous null alleles in WFS1 cause Wolfram syndrome, a rare, recessive disorder characterised by earlyonset diabetes with a non-autoimmune origin (27) , and a heterozygous mutation segregates with adult-onset diabetes in a large family (28) . Our most unexpected finding is perhaps the significant AEI for CAMK2B. This gene is in close proximity to GCK, the gene which encodes glucokinase, a key enzyme involved in the first rate-limiting step of glucose metabolism in the beta cell, and a gene where heterozygous inactivating mutations cause persistent, mild hyperglycaemia and homozygous inactivating mutations cause permanent neonatal diabetes (29) . Characterisation of the effects of the type 2 diabetes-associated SNP at this locus on glycaemic traits show a strong association with fasting glucose (7), further implicating GCK as the causative gene. One cannot rule out however a role for variation in CAMK2B levels affecting beta cell function given that this gene encodes a calcium/calmodulin-dependent protein kinase that has been shown to be involved in coupling Ca 2+ entry with insulin secretion (30) (31) (32) , and that this isoform is the predominant form in pancreatic beta cells (31; 33) . Little is known about HMG20A function in human islets but its involvement in neuronal differentiation (34; 35) may point towards a similar function in the neuronal-like beta cell.
Whilst we have identified AEIs in genes implicated by type 2 diabetes GWAS in human islets it is not altogether clear whether altered expression of these genes in islets is the primary mechanism leading to changes in disease susceptibility. The most recent and largest study to date examining the effect of T2D GWAS variants on continuous glycaemic traits reports 12/36 loci examined showing defects in beta cell function, whilst only 4/36 were associated with insulin sensitivity measures (7) . Of the 12 loci associated with defects in beta cell function we report AEI of SLC30A8 and CAMK2B at the SLC30A8 and GCK loci, SNPs exhibiting significant AEI (unadjusted p<0.05) shown in bold.*Adjusted using Benjamini-Hochberg false discovery rate
